Dactolisib (BEZ235, NVP-BEZ235)

Catalog No.S1009

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.

Cited by 88 Publications

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nature, 2017, 728-732

PubMed: 28321130 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )
Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )
J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )
Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )
Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )
J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )
Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

11 Customer Reviews

Level of phospho-proteins in RTK and PI3K–Akt–mTOR pathways in treated tumours, detected with western blot.

Nature, 2017, 728-732. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

A, ANOVA of IC50 values of the dual PI3K/mTOR inhibitor NVP-BEZ235 in 23 melanoma cell lines showing no significant difference in sensitivity to this compound in B-Raf mutant and Braf wild-type cells. B, decreases in pAkt and pP70S6K in a dose and time-dependent fashion in 2 melanoma cell lines treated with NVP-BEZ235. pP70S6K levels are undetectable at all concentrations and time points studied, whereas levels of pAkt start rising again after 4 hours of drug exposure in a dose-dependent fashion. C, clonogenic assays in 2 melanoma cell lines (YUVON and YUSIK) treated with NVP-BEZ235 at different concentrations. NVPBEZ235 was effective in inhibiting colony formation at low nanomolar concentrations.

Clin Cancer Res 2010 16, 6029-6039. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
Relative kinase activities of p110α mutants and the inhibitory effect of PI3K inhibitors against hotspot mutants of p110α. A, recombinant FLAG-tagged PI3K p110α/p85α protein complex produced in 293T cells was immunoprecipitated , and the immunoprecipitates were used for the quantitative PI3K-HTRF assay (32).

B, effect of three PI3K inhibitors (ZSTK474, LY294002, and NVP-BEZ235) on the enzymatic activity of two hotspot mutants (E545K and H1047R) p110α compared with the wild-type. No striking difference was observed in the IC50 concentrations of these inhibitors between wild-type and mutant p110α.

Cancer Res 2010 70, 4982-4994. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

ZSTK474 and GDC-0941 selectively inhibit class I PI3K over mTOR. (A) Inhibition profiles of the selected five PI3K inhibitors for mTOR. Data shown are mean±SD (n = 3), representative of 2 or 3 independent experiments. (B) IC50 values of the PI3K inhibitors for mTOR. (C) Selectivity of each PI3K inhibitor for PI3Ka over mTOR. The selectivity index is expressed as the ratio of the IC50 value for mTOR over that for PI3Ka. The IC50 values of ZSTK474, NVP-BEZ235 and LY294002 for PI3Ka are 0.016, 0.007 and 0.6 μM, respectively, as reported previously by us.

Eur J Cancer 2010 46, 1111-1121. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
Three-dimensional responses of MCF7/IGF-1R cells to TAM (1 μM), E2 and IGF-1. Compared to parental MCF7 cells (a), MCF7/IGF-1R cells (b) in three-dimensional (3D) culture formed bigger acini in response to IGF-1 stimulation and displayed significant TAM resistance when treated with TAM (1 μM) + E2 + IGF-1, which was removable by kinase inhibitors BMS-536924, U0126 and BEZ235 (c). Cells (10,000/well) were seeded in 96-well plates. Acini were formed on 100% Matrigel and cultured for 14 days in starving medium containing 2% Matrigel and 5% charcoal/dextran-stripped fetal bovine serum with the treatments as indicated. Concentrations used: TAM (1 μM), E2 (1 nM) and IGF-1 (100 ng/mL). Confocal image original magnification, × 20. Red, rhodamine phalloidin (actin). Blue, Hoechst blue stain. Results are representative of two individual experiments.

Breast Cancer Res 2011 13, R52. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

TAM (10 nM) agonistic behavior in MCF7/IGF-1R cells is not inhibited by phosphatidylinositol 3-kinase/Akt inhibitor BEZ235. (a) Inhibitory effects of kinase inhibitors BMS-536924, U0126 and BEZ235 on agonistic effect of TAM (10 nM) in the presence of IGF-1 (100 ng/mL). **P < 0.01. (b) Inhibitory effects of phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor BEZ235 at various dose ranges on IGF-1R signaling. (c) Agonistic behavior of TAM (10 nM) in response to BEZ235 kinase inhibitor. (-), no BEZ235. Results are representative of three independent experiments. Data are expressed as means ± SD.

Breast Cancer Res 2011 13:R52. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
(B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

Transl Oncol, 2016, 9(3):197-202. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

The effects of LY294002, rapamycin and NVP-BEZ235 on activation of PI3K-Akt-mTOR pathway in hepatocytes. (a) The mRNA expression (PI3K, Akt, mTOR, raptor) by Real-Time PCR, (b) protein expression (PI3K, Akt, mTOR, S6K) by ELISA kits; (c) protein expression of S6K and P-S6K by western blotting. The different letters indicated significant differences (P <0.05). LY = LY294002; rapa = rapamycin; NVP = NVP-BEZ235.

Animal, 2016, 10(8):1319-27. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
After starved in serum-free medium for 24h,breast cancer cells incubated with the indicated concentrations of BEZ235 for 3h,followed by 20-minute stimulation of 100ng/ml EGF.

Dr. Zhang of Tianjin Medical University. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

After starved in serum-free medium for 24h,breast cancer cells incubated with the indicated concentrations of BEZ235 for 3h,followed by 20-minute stimulation of 100ng/ml EGF.

Dr. Zhang of Tianjin Medical University. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
FIG. 4. Phospholipase A2 group 4A (PLA2G4A) expression was increased after BEZ235 treatment in basal-like xenografts. The bar graph shows the quantification of the immunoblots (mean±SD). PLA2G4A, Ethanolamine kinase 1 and 2 (ETNK1/2), Choline kinase alpha/beta (ChoKA/B), and β-actin protein expression were examined by immunoblotting of tissue samples after MRS experiments [control group (n= 5) and BEZ235-treated group (n=7)]. This demonstrated a higher expression of PLA2G4A protein ( P=0.005), but no changes in ETNK1 and ChoKA/B in samples from basal-like xenografts treated with BEZ235.

Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	NETMXVVCdnSrbXnjdo9jcWGuIFHzd4F6		M2fj[FE5KGh?	NWO4V3BNTE2VTx?=	MYfBcpRqfHK7cHHuc5NwdWGuIHHjeIl3cXS7IIfpeIghTUN3MDDv[kAxNjByMkWg{txO	MWGyOFgxPTl2Nh?=
MCF7	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zURVAvODFvMUCwJO69VQ>?	MWO0PEBp	MVzEUXNQ	NH7nPFhKSzVyPUCuO\|Mh\|ryP	NULXWYNtOjN6N{G5NFQ>
HCT116	M33Ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTxNE4xOS1zMECg{txO	M{TIUVQ5KGh?	MmnzSG1UVw>?	NIXxN4ZKSzVyPUGuNVYh\|ryP	MW[yN\|g4OTlyNB?=
U87MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHHTldOOC5yMT2xNFAh\|ryP	NVjkS4toPDhiaB?=	Mnz1SG1UVw>?	MnLQTWM2OD1zLkOyJO69VQ>?	NULwTG4zOjN6N{G5NFQ>
HBC4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFryb\|kxNjBzLUGwNEDPxE1?	M3fvd\|Q5KGh?		MmPYUI9oKEeLNUC9MVgvPjFiTR?=	MkHYNlI{OzZ{NE[=
BSY1	NGCyUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYGwMlAyNTFyMDFOwG0>	MlHsOFghcA>?		NIjzT3BNd2diR1m1NF0uQC52ODDN	NUTa[ZBJOjJ\|M{[yOFY>
HBC5	NX2z[mhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUWwMlAyNTFyMDFOwG0>	NGnPO4U1QCCq		M1\Ke2xw\yCJSUWwQU04Njh5IF2=	MXKyNlM{PjJ2Nh?=
MCF7	NFr0O2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX:wMlAyNTFyMDFOwG0>	M{XsRlQ5KGh?		M3TQdmxw\yCJSUWwQU05NjF4IF2=	NHrmd2IzOjN\|NkK0Oi=>
MDA-MB-231	M2XrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXuwMlAyNTFyMDFOwG0>	MljnOFghcA>?		MoHDUI9oKEeLNUC9MVgvODliTR?=	MWSyNlM{PjJ2Nh?=
U251	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHuOGUxNjBzLUGwNEDPxE1?	MnXFOFghcA>?		NFzTVJBNd2diR1m1NF0uPy54NjDN	NYnJU\|N6OjJ\|M{[yOFY>
SF268	MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XOSVAvODFvMUCwJO69VQ>?	MYO0PEBp		NFzGWoJNd2diR1m1NF0uPy57MjDN	MUWyNlM{PjJ2Nh?=
SF295	NWfudYZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{W0TlAvODFvMUCwJO69VQ>?	MUO0PEBp		M1HCdGxw\yCJSUWwQU05NjNzIF2=	NVfndHRUOjJ\|M{[yOFY>
SF539	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3pPJpVOC5yMT2xNFAh\|ryP	MonsOFghcA>?		NYLQWpllVG:pIFfJOVA:NThwNUmgUS=>	Mm\sNlI{OzZ{NE[=
SNB75	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVOwMlAyNTFyMDFOwG0>	MVq0PEBp		MVrMc4chT0l3ME2tPE42QCCP	M2HoV\|IzOzN4MkS2
SNB78	NVHuU2N7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTYSWoxNjBzLUGwNEDPxE1?	MYW0PEBp		M4nxXGxw\yCJSUWwQU05NjZ3IF2=	NH;hRoQzOjN\|NkK0Oi=>
HCC2998	NGXObmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\vS3VZOC5yMT2xNFAh\|ryP	MlLqOFghcA>?		NH:zVm9Nd2diR1m1NF0uQC5yNTDN	NH7UcJozOjN\|NkK0Oi=>
KM12	MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnZTYMxNjBzLUGwNEDPxE1?	NGH4ZmM1QCCq		NWKxT5VJVG:pIFfJOVA:NTdwNUSgUS=>	MnvGNlI{OzZ{NE[=
HT-29	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7nNE4xOS1zMECg{txO	M1SxOFQ5KGh?		MX7Mc4chT0l3ME2tO{44PSCP	M4\pXVIzOzN4MkS2
HCT15	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHscGQxNjBzLUGwNEDPxE1?	MYS0PEBp		NGfDbINNd2diR1m1NF0uQC5yMzDN	NXyxPGhDOjJ\|M{[yOFY>
HCT116	NWfJZmttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVqwMlAyNTFyMDFOwG0>	MYi0PEBp		MYjMc4chT0l3ME2tO{43OSCP	MmruNlI{OzZ{NE[=
NCI-H23	NIHtSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NECzb4IxNjBzLUGwNEDPxE1?	MXq0PEBp		MleyUI9oKEeLNUC9MVcvPjRiTR?=	NFjPNYEzOjN\|NkK0Oi=>
NCI-H226	NUnPeZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOwMlAyNTFyMDFOwG0>	MVm0PEBp		NYnJZ4ZHVG:pIFfJOVA:NThwNESgUS=>	MmW5NlI{OzZ{NE[=
NCI-H522	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHxSVExNjBzLUGwNEDPxE1?	NUDKXVdUPDhiaB?=		MojzUI9oKEeLNUC9MVgvPDViTR?=	NXz3TY02OjJ\|M{[yOFY>
NCI-H438	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUCwMlAyNTFyMDFOwG0>	M3PBfFQ5KGh?		MVvMc4chT0l3ME2tPE4yOSCP	MmrsNlI{OzZ{NE[=
A549	M4DGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYmwMlAyNTFyMDFOwG0>	NXy3R2VHPDhiaB?=		MoCzUI9oKEeLNUC9MVgvODdiTR?=	NHjpTXAzOjN\|NkK0Oi=>
DMS273	NHnN[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MViwMlAyNTFyMDFOwG0>	Mn3OOFghcA>?		NE\nWFhNd2diR1m1NF0uPy56MDDN	MVSyNlM{PjJ2Nh?=
DMS114	NUfafGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfQNE4xOS1zMECg{txO	MknaOFghcA>?		NHniVXJNd2diR1m1NF0uQC5\|OTDN	NX;zdHVHOjJ\|M{[yOFY>
LOXIMVI	M2\mW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7udlIxNjBzLUGwNEDPxE1?	NI\YfJE1QCCq		M{LBWWxw\yCJSUWwQU05NjZ4IF2=	NVPpeYN6OjJ\|M{[yOFY>
OVCAR3	NFPWeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjrUZUxNjBzLUGwNEDPxE1?	NF;ESYw1QCCq		MWrMc4chT0l3ME2tPE4yPyCP	NYrDbYtuOjJ\|M{[yOFY>
OVCAR4	MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVL3V\|BMOC5yMT2xNFAh\|ryP	MluyOFghcA>?		M{TvNGxw\yCJSUWwQU05NjV6IF2=	MWCyNlM{PjJ2Nh?=
OVCAR5	M2DCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jYTFAvODFvMUCwJO69VQ>?	NUnBd5FDPDhiaB?=		NGXvTW5Nd2diR1m1NF0uPy53NzDN	NIXuT2wzOjN\|NkK0Oi=>
OVCAR8	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLHeFMxNjBzLUGwNEDPxE1?	NHLsWZI1QCCq		MV\Mc4chT0l3ME2tO{45PCCP	MXiyNlM{PjJ2Nh?=
SKOV3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWwMlAyNTFyMDFOwG0>	NWHXc\|U2PDhiaB?=		M13PWGxw\yCJSUWwQU05NjRzIF2=	MVmyNlM{PjJ2Nh?=
RXF631L	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moj4NE4xOS1zMECg{txO	MVK0PEBp		NHfMfoNNd2diR1m1NF0uQC5{MTDN	NF\KPIQzOjN\|NkK0Oi=>
ACHN	NWj3OWdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[zW28xNjBzLUGwNEDPxE1?	M{TnfFQ5KGh?		Mn7TUI9oKEeLNUC9MVcvQTViTR?=	Ml7nNlI{OzZ{NE[=
St-4	NES4eGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXkcJoxNjBzLUGwNEDPxE1?	MoDXOFghcA>?		MVPMc4chT0l3ME2tO{41PyCP	NGLNfHUzOjN\|NkK0Oi=>
MKN1	NHzWbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2D5RVAvODFvMUCwJO69VQ>?	MUm0PEBp		NFvDRmJNd2diR1m1NF0uQC52MTDN	NF3HV5EzOjN\|NkK0Oi=>
MKN7	MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV[wMlAyNTFyMDFOwG0>	M3PPZVQ5KGh?		M{nCcmxw\yCJSUWwQU04NjZ6IF2=	M2XqXlIzOzN4MkS2
MKN28	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDablQxNjBzLUGwNEDPxE1?	NWrPXmF3PDhiaB?=		M2S3UGxw\yCJSUWwQU04NjB5IF2=	MViyNlM{PjJ2Nh?=
MKN45	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXqbmUxNjBzLUGwNEDPxE1?	M4\5blQ5KGh?		NHHj[4VNd2diR1m1NF0uQC5\|NDDN	MknrNlI{OzZ{NE[=
MKN74	NW\oT3M1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWOwMlAyNTFyMDFOwG0>	MmDsOFghcA>?		M1js[mxw\yCJSUWwQU04NjR{IF2=	NFPsbJczOjN\|NkK0Oi=>
DU145	Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S3WVAvODFvMUCwJO69VQ>?	NEHPOmU1QCCq		NFOwZ5pNd2diR1m1NF0uQC5zNjDN	M1;SVlIzOzN4MkS2
PC3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\4NE4xOS1zMECg{txO	M3K1cVQ5KGh?		NH;GcZFNd2diR1m1NF0uQC54NjDN	NIjUU5AzOjN\|NkK0Oi=>
Trypanosoma brucei brucei	Ml7FSpVv[3Srb36gRZN{[Xl?	NInMd5MzODBibl2=	NVrucFZkOTJiaB?=	NITHXYFFVVOR	MYjE[YNz\WG\|ZTDpckBxcG:\|cHjveIllgWxiaX7vd4l1d2xicHjvd5Bp[XSnIHzleoVt	NHm1W5kzPDhyNUm0Oi=>
Trypanosoma brucei brucei	MXrGeY5kfGmxbjDBd5NigQ>?		M1LOTFE5KGh?	NVn3d5JoTE2VTx?=	MkS5TY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?	NGD4RZozPDhyNUm0Oi=>
Trypanosoma brucei brucei	M2T4cmZ2dmO2aX;uJGF{e2G7	MWOyNFAhdk1?	M1jQ[\|EzKGh?	M1HNW2ROW09?	MWfF[oZm[3Rib36gd5BpcW6pb335cIVqdiCuZY\lcC=>	NFPyZWIzPDhyNUm0Oi=>
Trypanosoma brucei brucei	MUHGeY5kfGmxbjDBd5NigQ>?	M3v1XFIxOCCwTR?=	M4PkXlEzKGh?	NWC0XW9kTE2VTx?=	NH\UU\|dG\m[nY4Sgc44heGixc4DoZZRq\HmuY3jvcIlv\SCuZY\lcC=>	MUGyOFgxPTl2Nh?=
UM-UC-3	M2mzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4ThWmlEPTB;M{G1JJBO	NXHRZ5BUW0GQR1XS
SBC-1	Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{e5OWlEPTB;N{SyJJBO	MW\TRW5ITVJ?
MKN1	MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mke1TWM2OD1{Lkigcm0>	NX\uUYhtW0GQR1XS
NCI-H720	MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3z3[GlEPTB;Mz61O{BvVQ>?	M1y3UnNCVkeHUh?=
BFTC-909	NIPifYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYD1PHo2UUN3ME2zMlcyKG6P	M1fFWnNCVkeHUh?=
BPH-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HLVGlEPTB;ND63OkBvVQ>?	MnfLV2FPT0WU
PC-3	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXhSYxKSzVyPUWuNFkhdk1?	M2\wb3NCVkeHUh?=
AN3-CA	M{DBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrwfWlKSzVyPUWuOVYhdk1?	MUnTRW5ITVJ?
HN	MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzL[2NKSzVyPUWuPVYhdk1?	M13NXHNCVkeHUh?=
HCC2218	NGH1O5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonxTWM2OD14Lk[xJI5O	MUXTRW5ITVJ?
KP-4	MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDDcWNKSzVyPUegcm0>	NFX4bZpUSU6JRWK=
LU-139	NWDSNXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTdwN{egcm0>	MXjTRW5ITVJ?
ETK-1	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFu0RolKSzVyPUeuPFghdk1?	MoDzV2FPT0WU
Ramos-2G6-4C10	MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXVcIt4UUN3ME24MlQ6KG6P	MUDTRW5ITVJ?
MHH-PREB-1	M{S0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TaSWlEPTB;OT6xNkBvVQ>?	M4XWcXNCVkeHUh?=
DU-4475	NUDpWFltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TaSGlEPTB;OT60OEBvVQ>?	NG\iR\|NUSU6JRWK=
NCI-H1666	MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTlwN{Ggcm0>	MmHRV2FPT0WU
CAMA-1	NULDcYlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnLTWM2OD17Lkigcm0>	NHXFUHVUSU6JRWK=
TYK-nu	NUPQSnpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XqcmlEPTB;OT65OEBvVQ>?	NYfqTWFVW0GQR1XS
MFE-280	MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzmTZA1UUN3ME25Mlk6KG6P	MnGzV2FPT0WU
A549	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLJTWM2OD1zMD6xOEBvVQ>?	MUXTRW5ITVJ?
769-P	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjtSlJ1UUN3ME2xNE41PCCwTR?=	NYjvUHo1W0GQR1XS
L-363	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGX4cY5KSzVyPUGwMlY6KG6P	MYHTRW5ITVJ?
ES8	NWnmO5luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rldGlEPTB;MUCuPUBvVQ>?	MXXTRW5ITVJ?
PA-1	M{TTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zVW2lEPTB;MUGuPFIhdk1?	NYPRc4Z3W0GQR1XS
Mewo	NU\WZXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHUVll6UUN3ME2xNU46QSCwTR?=	NYDwdpplW0GQR1XS
HSC-3	M3XQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\SeFZKSzVyPUGyMlIyKG6P	MWHTRW5ITVJ?
H4	NU\VVYJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nYZ2lEPTB;MUKuOlchdk1?	NUDFcXJlW0GQR1XS
BB65-RCC	M1\nU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fQWGlEPTB;MUKuO\|Ihdk1?	MkDSV2FPT0WU
NCI-H1793	NXHIOHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnHTWM2OD1zMj64NkBvVQ>?	NXTHT\|Y3W0GQR1XS
KARPAS-45	M{Tsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHENpFKSzVyPUGzMlUyKG6P	MVnTRW5ITVJ?
GCT	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTF\|Lk[4JI5O	NGf1RmxUSU6JRWK=
EoL-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHS5d21KSzVyPUGzMlk{KG6P	MVLTRW5ITVJ?
LB2241-RCC	M2fXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjWN4pKSzVyPUG0MlAyKG6P	M1;1WHNCVkeHUh?=
ES5	NG[yW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjXUYJvUUN3ME2xOE44PCCwTR?=	NYrwOoRIW0GQR1XS
LOXIMVI	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTxTWM2OD1zND65PUBvVQ>?	MUXTRW5ITVJ?
COR-L105	M3fkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{m4VWlEPTB;MUWuNFQhdk1?	NIPXcXhUSU6JRWK=
P12-ICHIKAWA	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\rTWM2OD1zNT6xJI5O	MoHRV2FPT0WU
CHL-1	NVv0W5Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXJe49wUUN3ME2xOU41PSCwTR?=	MnLNV2FPT0WU
VMRC-RCZ	M1\zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPRN4tKSzVyPUG1MlY{KG6P	M1nFbnNCVkeHUh?=
HH	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn:1TWM2OD1zNT63JI5O	NF\4NplUSU6JRWK=
NUGC-3	NHv0cYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTF4LkO0JI5O	NWjaR\|hpW0GQR1XS
EGI-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTF4LkSzJI5O	M1fhOnNCVkeHUh?=
OS-RC-2	NEDKTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTF4LkS3JI5O	MXjTRW5ITVJ?
MOLT-16	NUPGWoNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnnWZhKSzVyPUG3MlE2KG6P	MlzvV2FPT0WU
NCI-H209	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljJTWM2OD1zNz6yPUBvVQ>?	NF76N3lUSU6JRWK=
697	Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\QWGlEPTB;MUeuOFMhdk1?	MkK5V2FPT0WU
D-56MG	NEXsOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTF5Lk[5JI5O	M4j1O3NCVkeHUh?=
VA-ES-BJ	NVzGfXU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTF5LkizJI5O	M37HOHNCVkeHUh?=
EW-16	NH\OSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HmPGlEPTB;MUiuNFQhdk1?	NVe1N3R6W0GQR1XS
HGC-27	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDhUFRKSzVyPUG4MlA3KG6P	NVLBRlllW0GQR1XS
ES7	M3\4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPsd29TUUN3ME2xPE4xQSCwTR?=	Mom5V2FPT0WU
HuH-7	M2H6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTF6LkSgcm0>	MmDMV2FPT0WU
BCPAP	NWSwU3dkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fKfGlEPTB;MUiuOlUhdk1?	M3jNPXNCVkeHUh?=
SW1710	NYSyOZNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13RdGlEPTB;MUiuO\|Ihdk1?	M3[3cnNCVkeHUh?=
IST-MEL1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLzVXJRUUN3ME2xPE44PyCwTR?=	MXfTRW5ITVJ?
SF295	NES3NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXwTWM2OD1zOD65N{BvVQ>?	NGj1T3lUSU6JRWK=
RPMI-7951	NUfzbY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3QT2xKSzVyPUG5MlI5KG6P	MleyV2FPT0WU
SF126	Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjTdW9KSzVyPUG5MlQyKG6P	NXS3Rnp2W0GQR1XS
GAMG	MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TKdWlEPTB;MUmuOFghdk1?	M2XqV3NCVkeHUh?=
KNS-81-FD	NFO1UZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13qTmlEPTB;MUmuOVQhdk1?	MnvmV2FPT0WU
RT-112	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPYUmdKSzVyPUG5MlY3KG6P	Mm\HV2FPT0WU
DEL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoC1TWM2OD1{MD60PUBvVQ>?	NGrSdFRUSU6JRWK=
CGTH-W-1	M3fIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTJyLk[zJI5O	Mk\lV2FPT0WU
HOS	NGnjdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTJzLkC2JI5O	MlfjV2FPT0WU
ES4	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4O3TmlEPTB;MkGuNFghdk1?	MkjjV2FPT0WU
RXF393	NWLFNowzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLxdGlKSzVyPUKxMlQ2KG6P	NILsXVNUSU6JRWK=
NCI-H2030	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoKzTWM2OD1{MT61NkBvVQ>?	MlXUV2FPT0WU
YH-13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljCTWM2OD1{MT64PEBvVQ>?	NE[0O\|ZUSU6JRWK=
HT-1080	NIfYZ\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJzLkmzJI5O	Mm\2V2FPT0WU
NCI-SNU-1	NYXDNpJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;MNpJEUUN3ME2yNU46PSCwTR?=	M3zFT3NCVkeHUh?=
G-402	M2TCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlW4TWM2OD1{Mj6xOkBvVQ>?	NFG4fnlUSU6JRWK=
786-0	MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXroUJo3UUN3ME2yNk4zQSCwTR?=	M2DqRnNCVkeHUh?=
ME-180	NFTqd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXkTWM2OD1{Mj60N{BvVQ>?	MlS5V2FPT0WU
NB69	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfNfWpKSzVyPUKyMlU{KG6P	M{DaNnNCVkeHUh?=
J-RT3-T3-5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnniTWM2OD1{Mj65OkBvVQ>?	NGPLeWpUSU6JRWK=
TGBC1TKB	NVvhUVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXQTWM2OD1{Mz6wOUBvVQ>?	NGq0WlFUSU6JRWK=
SW780	MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrxdFZKSzVyPUKzMlE{KG6P	MW\TRW5ITVJ?
MG-63	MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX63fVVQUUN3ME2yN{41PSCwTR?=	M{H5UnNCVkeHUh?=
BV-173	M1zNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLOTWM2OD1{Mz64O{BvVQ>?	NVfVXXdWW0GQR1XS
CAL-51	NFiy[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn35TWM2OD1{Mz64PUBvVQ>?	NF\KbmlUSU6JRWK=
A375	MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjoV4JKSzVyPUKzMlk{KG6P	NWrqc\|d1W0GQR1XS
MEL-HO	M1Sz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXSTWM2OD1{ND6wOEBvVQ>?	Mn6zV2FPT0WU
EFO-27	NWX1Om5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4m1fmlEPTB;MkSuN\|Mhdk1?	NGXHcplUSU6JRWK=
Hs-578-T	M4jk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkKzTWM2OD1{ND61PEBvVQ>?	MkfOV2FPT0WU
NBsusSR	NYPDZppxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH73RVRKSzVyPUK0MlYhdk1?	NXzXUZdrW0GQR1XS
CTB-1	Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJ2Lk[3JI5O	NH\OVnFUSU6JRWK=
FTC-133	M1XPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPoTWM2OD1{NT6xJI5O	Mmn5V2FPT0WU
MOLT-4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTJ3LkGyJI5O	MX;TRW5ITVJ?
HO-1-N-1	M2O5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3FTWM2OD1{NT6xOUBvVQ>?	M1SzUnNCVkeHUh?=
ES3	NF75PWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPWdmRKSzVyPUK1MlIzKG6P	M2jDUXNCVkeHUh?=
TI-73	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXrdIFKSzVyPUK1MlI5KG6P	NXL0W2Y{W0GQR1XS
MPP-89	NFvYWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHq4NVhKSzVyPUK1MlMzKG6P	MmDSV2FPT0WU
KYSE-150	NWfSUlA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJ3Lki5JI5O	MXrTRW5ITVJ?
LXF-289	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Ow[WlEPTB;Mk[uNFQhdk1?	NWriR2c6W0GQR1XS
SK-LU-1	NWryXJRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTJ4LkG3JI5O	MYnTRW5ITVJ?
HOP-92	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\DTWM2OD1{Nj60PEBvVQ>?	Mn65V2FPT0WU
HuO9	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjyV3lNUUN3ME2yOk44PiCwTR?=	M3LteHNCVkeHUh?=
SW962	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTJ4Lke2JI5O	NHWzNGtUSU6JRWK=
RS4-11	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;jV5BKSzVyPUK2MlkyKG6P	MlfMV2FPT0WU
NCI-H292	NEe3blRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHroOphKSzVyPUK3JI5O	M4D2SXNCVkeHUh?=
DB	M2rjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TjdWlEPTB;MkeuN\|Yhdk1?	NUC5V4xIW0GQR1XS
SW1088	M1;zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTJ6LkK5JI5O	M4fFd3NCVkeHUh?=
A204	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPjTWM2OD1{OD60O{BvVQ>?	NUfWNnAxW0GQR1XS
A3-KAW	M{n1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfzW2pHUUN3ME2yPE43PCCwTR?=	MX3TRW5ITVJ?
MV-4-11	NGXJZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWW3cpM6UUN3ME2yPE44KG6P	NFXHT\|RUSU6JRWK=
ES1	M1r3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmS0TWM2OD1{OD64OEBvVQ>?	NGLibYdUSU6JRWK=
ONS-76	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGH2XFhKSzVyPUK5MlA2KG6P	MV;TRW5ITVJ?
D-263MG	NVS5dYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvqZVdNUUN3ME2yPU4{PSCwTR?=	Ml[5V2FPT0WU
U-2-OS	NV\nUo1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M370RWlEPTB;MkmuOUBvVQ>?	NWrZVGY2W0GQR1XS
T98G	M3;ZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXn5e4NJUUN3ME2yPU45QCCwTR?=	MVvTRW5ITVJ?
GI-ME-N	MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTJ7LkmxJI5O	M1q1RXNCVkeHUh?=
BHT-101	M1jES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLONYpKSzVyPUOwMlA2KG6P	M2jsRnNCVkeHUh?=
NOS-1	NV7sPVVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTNyLkGyJI5O	NGXjRZZUSU6JRWK=
AsPC-1	MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkizTWM2OD1\|MD6yJI5O	NVqyN3VrW0GQR1XS
QIMR-WIL	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTNyLk[gcm0>	MYXTRW5ITVJ?
JVM-3	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTNyLkizJI5O	MnfJV2FPT0WU
KU-19-19	M3fkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTNzLkGzJI5O	MVHTRW5ITVJ?
OVCAR-8	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYO3dXhyUUN3ME2zNU4zPiCwTR?=	NVX4UnJxW0GQR1XS
BEN	NFfhXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrmTWM2OD1\|MT62N{BvVQ>?	M17rUHNCVkeHUh?=
BE-13	NUXzb\|lWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrENpNKSzVyPUOxMlgzKG6P	NW\aOnRIW0GQR1XS
EW-18	NXe1U41tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWf1dndQUUN3ME2zNU45PiCwTR?=	NIjoW2VUSU6JRWK=
ECC10	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWOwNnAxUUN3ME2zNU46PSCwTR?=	NHzCbGdUSU6JRWK=
CTV-1	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmD0TWM2OD1\|Mj64NkBvVQ>?	NWfs[HZ5W0GQR1XS
COLO-800	M1jpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFG3UldKSzVyPUOyMlkzKG6P	NG\GNVhUSU6JRWK=
A2058	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTN\|LkK1JI5O	NV\HUnp1W0GQR1XS
VM-CUB-1	MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDqVmlLUUN3ME2zN{41OyCwTR?=	NViybWo3W0GQR1XS
Ca9-22	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTN\|LkW1JI5O	M1i4enNCVkeHUh?=
COLO-684	M3Tsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTN\|LkW4JI5O	MUHTRW5ITVJ?
RPMI-8226	NFnyOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkP3TWM2OD1\|Mz64NkBvVQ>?	M1y2XnNCVkeHUh?=
SK-NEP-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGP2fYlKSzVyPUO0MlE2KG6P	MnnRV2FPT0WU
Becker	M2LsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XTVWlEPTB;M{SuNlEhdk1?	NITyTJNUSU6JRWK=
NCI-H28	M{TURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{O1XWlEPTB;M{SuOFQhdk1?	NYfrN5p1W0GQR1XS
CAL-120	NXv0SYVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoKwTWM2OD1\|ND63NkBvVQ>?	M1;DR3NCVkeHUh?=
MDA-MB-157	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnKxTWM2OD1\|NT60NUBvVQ>?	MULTRW5ITVJ?
OVCAR-5	MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHSeoxKSzVyPUO1MlQ4KG6P	NYnSUVAxW0GQR1XS
LAMA-84	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHHbYlCUUN3ME2zOU45PyCwTR?=	M2jNOXNCVkeHUh?=
CAKI-1	NXPJO2VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTN4LkSzJI5O	NWjwSm5LW0GQR1XS
Daoy	NFnye4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PsbGlEPTB;M{[uO{BvVQ>?	NH;heWFUSU6JRWK=
CAL-62	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4C1bWlEPTB;M{[uPFYhdk1?	Ml;4V2FPT0WU
8-MG-BA	M3Lncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nQemlEPTB;M{euNlUhdk1?	M4TucHNCVkeHUh?=
8505C	NGHabGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PkcGlEPTB;M{euOVEhdk1?	NFrRRmhUSU6JRWK=
LNCaP-Clone-FGC	M4L0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{n3WWlEPTB;M{euOVkhdk1?	NIXV[HdUSU6JRWK=
CAL-39	NHK1TlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIKxcmRKSzVyPUO3Mlkhdk1?	NWTLZ3VwW0GQR1XS
MN-60	NEm4fYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPLV3l4UUN3ME2zO{46PiCwTR?=	MUjTRW5ITVJ?
RKO	NIfnOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXjbVc2UUN3ME2zPE4{OyCwTR?=	Mm\RV2FPT0WU
U251	NHnqXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW[zfIhuUUN3ME2zPE41OyCwTR?=	MX;TRW5ITVJ?
SJSA-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTN6LkW0JI5O	MYHTRW5ITVJ?
CAL-12T	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTN6Lk[gcm0>	NEK1Oo9USU6JRWK=
HCC1419	NFO0SnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvmXlJKSzVyPUO4MlcyKG6P	M3\B[nNCVkeHUh?=
CO-314	NH;wfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojyTWM2OD1\|OD63OEBvVQ>?	MnPvV2FPT0WU
LB1047-RCC	NWD0S\|JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nDc2lEPTB;M{iuPFEhdk1?	NWS5PIpLW0GQR1XS
A101D	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTN6Lkm3JI5O	MoTBV2FPT0WU
MDA-MB-175-VII	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4SyRWlEPTB;M{muOVEhdk1?	MXzTRW5ITVJ?
MZ2-MEL	NVPieG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzNUmJTUUN3ME2zPU43PiCwTR?=	NHWyOpNUSU6JRWK=
NB5	NGPzWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnXclFrUUN3ME20NE43PCCwTR?=	Mo\NV2FPT0WU
G-401	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXXZY1XUUN3ME20NE45OiCwTR?=	NHzrTFFUSU6JRWK=
HT	M3XjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rxRmlEPTB;NEGuNFIhdk1?	NUPaeG5rW0GQR1XS
8305C	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17MbWlEPTB;NEGuPFchdk1?	NF7JfVJUSU6JRWK=
BHY	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3DTWM2OD12Mj63NkBvVQ>?	MX;TRW5ITVJ?
NTERA-S-cl-D1	Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTR\|IH7N	MWDTRW5ITVJ?
T-24	NH\hcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHL2Xo5KSzVyPUSzMlg{KG6P	MorNV2FPT0WU
EPLC-272H	NXX2To5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3kTWM2OD12ND6zPUBvVQ>?	NVewR3lXW0GQR1XS
PSN1	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonOTWM2OD12ND60JI5O	Moe1V2FPT0WU
NCI-H2452	NWHne\|NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfiTWM2OD12ND61PEBvVQ>?	NYTvTXZOW0GQR1XS
KS-1	NYGzb482T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\BfWlEPTB;NESuOlYhdk1?	NUTSNGRjW0GQR1XS
HD-MY-Z	NVn0e\|Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXNRpJmUUN3ME20OE46OiCwTR?=	NX;yR2M2W0GQR1XS
KNS-62	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LKSGlEPTB;NEWuN\|ghdk1?	NEO0e2VUSU6JRWK=
NOMO-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTR3Lki3JI5O	M4WxXXNCVkeHUh?=
SK-HEP-1	M4XGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTR4LkC0JI5O	NWjBOXNtW0GQR1XS
IGR-1	NEDoXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfMWnVKSzVyPUS2MlE{KG6P	M3TqWXNCVkeHUh?=
KYSE-180	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTR4LkG3JI5O	M{DxdXNCVkeHUh?=
EW-22	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTR4LkKgcm0>	MlThV2FPT0WU
NCI-H1355	M2i1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LtdWlEPTB;NE[uN\|Qhdk1?	MV;TRW5ITVJ?
DOHH-2	M2XldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PD[WlEPTB;NE[uN\|chdk1?	NUX0TINmW0GQR1XS
A4-Fuk	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTR4LkWyJI5O	NUjHO3VwW0GQR1XS
PC-14	NWPWNGxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHBb4Z5UUN3ME20Ok42PyCwTR?=	M{X6XXNCVkeHUh?=
TE-5	NGHLR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPvXWZjUUN3ME20Ok45PCCwTR?=	NW[xNYpqW0GQR1XS
LB996-RCC	M2TFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTR5LkG5JI5O	M3nrR3NCVkeHUh?=
NCI-H1623	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTR5Lke2JI5O	MnrCV2FPT0WU
NCI-H1155	M3LoZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nvT2lEPTB;NEiuN\|Ihdk1?	M3HjT3NCVkeHUh?=
LoVo	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzHUI51UUN3ME20PE41KG6P	M3\vcHNCVkeHUh?=
MCF7	Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXwTWM2OD12OD61PEBvVQ>?	M3;IU3NCVkeHUh?=
AGS	M2TSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTR6Lke3JI5O	NXvHVGVZW0GQR1XS
PFSK-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XQWmlEPTB;NEmuNFYhdk1?	NEP0ZVBUSU6JRWK=
22RV1	MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTR7LkC5JI5O	M1\JZXNCVkeHUh?=
COR-L23	MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\ITWM2OD12OT6xOkBvVQ>?	M1Xvc3NCVkeHUh?=
D-283MED	NWe3ZpI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDBTWM2OD12OT62NUBvVQ>?	NHHiXopUSU6JRWK=
SW982	M{Djb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTySG5wUUN3ME20PU46OSCwTR?=	M{HqN3NCVkeHUh?=
SW620	MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTVyLkO2JI5O	MVLTRW5ITVJ?
KYSE-140	NGnPNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LufmlEPTB;NUCuOVUhdk1?	MXHTRW5ITVJ?
GCIY	M3PZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:2OotKSzVyPUWwMlY4KG6P	NX:0SGppW0GQR1XS
MHH-ESS-1	NX;lXZJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zNRWlEPTB;NUGuPVUhdk1?	MnfYV2FPT0WU
D-423MG	NEfVS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInWRpdKSzVyPUWyMlA5KG6P	MnT1V2FPT0WU
SF539	NHnSe3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrPT2hKSzVyPUWyMlM2KG6P	NFf0U45USU6JRWK=
RPMI-2650	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTV{Lk[5JI5O	NXW2NJZCW0GQR1XS
GR-ST	NFLlb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXCe5NKSzVyPUWyMlg4KG6P	M2[xdHNCVkeHUh?=
YKG-1	NXXkZ2dJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPkXG14UUN3ME21N{BvVQ>?	MmfOV2FPT0WU
SK-MES-1	NF;We3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUWzdlZqUUN3ME21N{4zPiCwTR?=	NUjTTphyW0GQR1XS
HLE	M3jCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknjTWM2OD13Mz60O{BvVQ>?	MUHTRW5ITVJ?
RVH-421	NFL0T3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjhfVRKSzVyPUWzMlY4KG6P	MlzTV2FPT0WU
C32	NV\Gblh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPRbZlKSzVyPUWzMlg{KG6P	NYG2cIJTW0GQR1XS
GB-1	M2fPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXq5W3BnUUN3ME21OE4zKG6P	MmW5V2FPT0WU
SNB75	M4LITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\pTWM2OD13ND6yOkBvVQ>?	M2PkfHNCVkeHUh?=
EM-2	M2nx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlO2TWM2OD13ND60JI5O	NIO4U4dUSU6JRWK=
RH-1	NHvWV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PoPWlEPTB;NUSuO{BvVQ>?	MlLYV2FPT0WU
NKM-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnf4TWM2OD13ND64NUBvVQ>?	M{PWR3NCVkeHUh?=
NCI-H2405	M1ThVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfuTWM2OD13ND64PEBvVQ>?	NVXqZZJbW0GQR1XS
KYSE-450	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTV3LkG2JI5O	NHTR[HdUSU6JRWK=
A704	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HtfGlEPTB;NUWuOVkhdk1?	NH;Eb49USU6JRWK=
HAL-01	NYPtOGQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4P2TWlEPTB;NUWuPFMhdk1?	NFTUdWhUSU6JRWK=
TE-11	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTV3Lkm5JI5O	NEi0O45USU6JRWK=
DOK	NF2yXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnSVHpKSzVyPUW2MlAzKG6P	MmnEV2FPT0WU
KY821	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmG3TWM2OD13Nj6yJI5O	M1zySHNCVkeHUh?=
KGN	NF;VW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1eyWWlEPTB;NU[uN\|Ihdk1?	NF3BboZUSU6JRWK=
MC116	NEnLW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrPSYVvUUN3ME21O{45KG6P	NUTzSZh5W0GQR1XS
PANC-08-13	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTV6LkCxJI5O	Moj1V2FPT0WU
KE-37	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfUbFhKSzVyPUW4Mlc4KG6P	NUnCXFVVW0GQR1XS
KYSE-410	M3jHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkmwTWM2OD13OT60O{BvVQ>?	NHTIcZFUSU6JRWK=
RO82-W-1	NGHVXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjhSnREUUN3ME21PU46KG6P	MlnlV2FPT0WU
M14	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjocm9KSzVyPU[wMlA1KG6P	MV\TRW5ITVJ?
GI-1	NFfkXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTZyLkOgcm0>	M2TRdnNCVkeHUh?=
ML-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rafmlEPTB;NkCuOlIhdk1?	NHnXVFBUSU6JRWK=
BFTC-905	M3XRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV23S3Z[UUN3ME22NE43PSCwTR?=	M1n0THNCVkeHUh?=
DMS-273	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonsTWM2OD14MD64O{BvVQ>?	NGqwNFJUSU6JRWK=
MDA-MB-361	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPUTWM2OD14MTDuUS=>	MnfIV2FPT0WU
MSTO-211H	NWXwOmhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTZ\|LkWxJI5O	NUewcXV2W0GQR1XS
MEG-01	NVvPWVI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\GOZhFUUN3ME22N{42OiCwTR?=	M4H4ZXNCVkeHUh?=
M059J	M3PYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfNSHVKSzVyPU[zMlU5KG6P	MV\TRW5ITVJ?
LN-405	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTZ\|Lki1JI5O	Ml21V2FPT0WU
NCI-H1581	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jm[WlEPTB;NkSuNFMhdk1?	MlvFV2FPT0WU
TCCSUP	NH;JT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2P0VWlEPTB;NkSuOVMhdk1?	NGfl[mxUSU6JRWK=
SW872	M3LwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\VWGlEPTB;NkSuOVchdk1?	MlLMV2FPT0WU
KYSE-510	M2n0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nwTWlEPTB;NkWuO\|Uhdk1?	M{LqTnNCVkeHUh?=
NCI-H1792	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\ZTWM2OD14Nj6xOUBvVQ>?	NWTEfHYxW0GQR1XS
SW13	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnu2TWM2OD14Nj61JI5O	M2rZfnNCVkeHUh?=
TE-8	M37XVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrpTWM2OD14Nj61NkBvVQ>?	MVPTRW5ITVJ?
SCH	NHTvXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rxemlEPTB;NkeuNUBvVQ>?	M1XpUXNCVkeHUh?=
NEC8	Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moq2TWM2OD14Nz6yOEBvVQ>?	NGD1d3RUSU6JRWK=
HuO-3N1	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTZ5LkOxJI5O	NH:0ZZdUSU6JRWK=
EFM-19	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fMUmlEPTB;NkeuOUBvVQ>?	NVvkclRCW0GQR1XS
HEC-1	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PYdGlEPTB;NkeuOVIhdk1?	MnPXV2FPT0WU
T47D	M3fpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\pTWM2OD14Nz64O{BvVQ>?	NXPqVIVWW0GQR1XS
SNU-423	NXXyO3d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfMNZhKSzVyPU[3Mlk5KG6P	M2fYcHNCVkeHUh?=
WM-115	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzyZ\|NKSzVyPU[4MlE1KG6P	M2\2RXNCVkeHUh?=
CaR-1	M376fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX:2Snp6UUN3ME22PE4zPSCwTR?=	M{XHVXNCVkeHUh?=
KU812	NGn4cI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYruWFZUUUN3ME22PE43QSCwTR?=	MXvTRW5ITVJ?
AM-38	MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWe3XI1KUUN3ME22PU4{OSCwTR?=	NW\3bY84W0GQR1XS
KOSC-2	NYHGS3dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTZ7Lkm3JI5O	Mn:2V2FPT0WU
MC-IXC	MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTdyLkC4JI5O	NXz0dnlXW0GQR1XS
SCC-4	NVrwUIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTdzLkO4JI5O	Mnz1V2FPT0WU
Calu-3	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLxTWM2OD15MT65PEBvVQ>?	M1jUUHNCVkeHUh?=
RPMI-8866	MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3i2[2lEPTB;N{KuPFIhdk1?	NWH5TpJkW0GQR1XS
OVCAR-4	M{fTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTd\|LkO2JI5O	NX3lfVduW0GQR1XS
OAW-42	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmGwTWM2OD15Mz6zPUBvVQ>?	MWXTRW5ITVJ?
ATN-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTd\|Lki3JI5O	M2XiOnNCVkeHUh?=
CHP-212	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjKWpVVUUN3ME23OE46PSCwTR?=	NYW1RYJsW0GQR1XS
C2BBe1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHMdFZqUUN3ME23OU4xOyCwTR?=	MlPTV2FPT0WU
A498	NHyy[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7VPHpKUUN3ME23OU4yPSCwTR?=	M1jMVXNCVkeHUh?=
SH-4	NX3B[XU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTd3LkKxJI5O	M1ux[3NCVkeHUh?=
SNU-449	NXvYcFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrS[pdKSzVyPUe1Mlc6KG6P	MmPoV2FPT0WU
RD	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTd3Lki2JI5O	M4DuNXNCVkeHUh?=
PANC-03-27	NGXENmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnj[opKSzVyPUe2MlI2KG6P	M2LKRnNCVkeHUh?=
S-117	NVLQb5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nCSmlEPTB;N{[uNlchdk1?	M37CdHNCVkeHUh?=
SK-MEL-2	NF34bWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPvNlBKSzVyPUe2Mlc2KG6P	M3y4[3NCVkeHUh?=
LK-2	M{\X[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTd5LkC1JI5O	M1\EcnNCVkeHUh?=
CP50-MEL-B	NYL1OXJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLMSYVsUUN3ME23O{41KG6P	MmrZV2FPT0WU
647-V	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4e2OGlEPTB;N{iuNFchdk1?	NULnU4d6W0GQR1XS
LU-134-A	NUXxXFFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTd7LkCzJI5O	MoL5V2FPT0WU
5637	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXOVnFKSzVyPUe5MlI{KG6P	MmK4V2FPT0WU
NCI-H1437	M{[w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnyZXc{UUN3ME24NE42KG6P	MYTTRW5ITVJ?
NCI-H460	M3vTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFywSXNKSzVyPUixMlI{KG6P	M4LXe3NCVkeHUh?=
BxPC-3	NUS3bpBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjLeoY1UUN3ME24NU41PiCwTR?=	MkSyV2FPT0WU
CAN	Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Tr[mlEPTB;OEGuPFQhdk1?	NVjCbGVVW0GQR1XS
KINGS-1	MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlm4TWM2OD16Mj6zNkBvVQ>?	MWDTRW5ITVJ?
OCUB-M	NX3NVmNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTh{LkSxJI5O	Mny1V2FPT0WU
KALS-1	M3K3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfvTWM2OD16Mj61OEBvVQ>?	NHnzXJhUSU6JRWK=
OCI-AML2	NHP2WoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvubWN[UUN3ME24Nk43OSCwTR?=	MWjTRW5ITVJ?
A253	M2HsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLJVZlDUUN3ME24Nk43PSCwTR?=	NEfCNppUSU6JRWK=
LCLC-97TM1	NETB[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTh{Lki2JI5O	NYrxRVY4W0GQR1XS
NCI-H520	M2\mUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTBTWM2OD16Mz6wOkBvVQ>?	MnfqV2FPT0WU
P30-OHK	NGGzVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTh\|LkWgcm0>	NXTtZpFWW0GQR1XS
SBC-5	M2jMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTh\|LkWyJI5O	NWm1SmdvW0GQR1XS
HCE-T	NXfnS3d1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\JTWM2OD16Mz63OEBvVQ>?	NWPMO\|NNW0GQR1XS
JEG-3	MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nrSWlEPTB;OESuNUBvVQ>?	M3PQVnNCVkeHUh?=
KG-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTh2LkK0JI5O	MXPTRW5ITVJ?
MIA-PaCa-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TQe2lEPTB;OESuOVQhdk1?	NXPHdnh4W0GQR1XS
CAL-33	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTGWVhKSzVyPUi1MlA5KG6P	NFW1WYJUSU6JRWK=
639-V	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HKWGlEPTB;OEWuOFIhdk1?	NVHsbVNFW0GQR1XS
NCI-H1048	M3zwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTh4LkOxJI5O	M2K3U3NCVkeHUh?=
NCI-H1573	M{PLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTh5LkS4JI5O	MWTTRW5ITVJ?
NCI-H2228	M3joRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnjfpVKSzVyPUi4MlI3KG6P	NVfJbFVYW0GQR1XS
NB14	NWHKbI1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPmN4dKSzVyPUi4MlMhdk1?	MU\TRW5ITVJ?
SCC-25	M3TOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\tTWM2OD16OT64NkBvVQ>?	NUPGeW1PW0GQR1XS
A431	NYC3S3F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTh7Lkm3JI5O	MYLTRW5ITVJ?
SN12C	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPtTWM2OD17MD62NkBvVQ>?	MkfHV2FPT0WU
HuCCT1	NUPvWWxlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTlyLke2JI5O	M1v4fXNCVkeHUh?=
LS-123	NX7HZZhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTl{LkG4JI5O	M4LWVHNCVkeHUh?=
CAL-85-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXRTWM2OD17Mj60PEBvVQ>?	M{TLXnNCVkeHUh?=
ES6	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjrfIVKSzVyPUmyMlg{KG6P	MonCV2FPT0WU
NCI-H650	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTl2LkC5JI5O	M4\vTHNCVkeHUh?=
NCI-H446	Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljnTWM2OD17NT6xNkBvVQ>?	MXPTRW5ITVJ?
EW-13	M37rVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkThTWM2OD17NT63OUBvVQ>?	NVSxbld[W0GQR1XS
HSC-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1G2[GlEPTB;OUWuPFkhdk1?	MmLzV2FPT0WU
U031	NX;5W\|FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU[zO2hTUUN3ME25Ok44OyCwTR?=	NVrX[WpEW0GQR1XS
EW-11	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1yxdGlEPTB;OU[uPFghdk1?	M{fybnNCVkeHUh?=
GAK	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\NTWM2OD17OD65N{BvVQ>?	MXHTRW5ITVJ?
SK-OV-3	M1\BfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\iTVhKSzVyPUGwNE4xPyCwTR?=	M1fnN3NCVkeHUh?=
OMC-1	NV20bmVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NECxVFBKSzVyPUGwNE4yQCCwTR?=	M{LNcnNCVkeHUh?=
TK10	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjRTWM2OD1zMECuNlEhdk1?	MX7TRW5ITVJ?
EKVX	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFyMD62JI5O	MlnEV2FPT0WU
Detroit562	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nxbWlEPTB;MUCyMlE4KG6P	NXLFOHd5W0GQR1XS
SF268	NIXjXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTFyMj6zOEBvVQ>?	MnXuV2FPT0WU
SNU-387	M17z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fMR2lEPTB;MUC0MlE4KG6P	MnTXV2FPT0WU
MDA-MB-231	NV64Uo96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPXTWM2OD1zMEWuNFYhdk1?	MVLTRW5ITVJ?
NCI-H1563	Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTFyNT6xPEBvVQ>?	NU\1T\|ZyW0GQR1XS
D-502MG	MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXf0d4tjUUN3ME2xNFUvPyCwTR?=	MWfTRW5ITVJ?
A2780	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH76RotKSzVyPUGwOk41PyCwTR?=	MkP4V2FPT0WU
IA-LM	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1ftRmlEPTB;MUC3MlUyKG6P	M3j2SHNCVkeHUh?=
D-392MG	MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PUU2lEPTB;MUC3MlU1KG6P	M33GWXNCVkeHUh?=
MS-1	NGXvN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTFyNz63NUBvVQ>?	MX7TRW5ITVJ?
SW1990	NXzEeZI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13uNWlEPTB;MUC4MlU1KG6P	MonCV2FPT0WU
HEL	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmW5TWM2OD1zMEmuNlkhdk1?	Mni5V2FPT0WU
SW1573	M3TvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTFyOT6zNUBvVQ>?	NGXYb5NUSU6JRWK=
SW1783	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzYT3hKSzVyPUGxNE4zOiCwTR?=	M4r5OnNCVkeHUh?=
COLO-680N	Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFK5dVRKSzVyPUGxNE44PiCwTR?=	NFq0O2ZUSU6JRWK=
NCI-N87	NYryS4RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;KcWlEPTB;MUGxMlA1KG6P	MVfTRW5ITVJ?
SK-MEL-28	NIT5[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXoTWM2OD1zMUGuOVUhdk1?	NF[2V4FUSU6JRWK=
BT-20	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DjRmlEPTB;MUGyMlAyKG6P	MV;TRW5ITVJ?
NCI-H1648	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nhR2lEPTB;MUGzJI5O	M3[zVHNCVkeHUh?=
no-11	MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe5NY4zUUN3ME2xNVMvOjhibl2=	MVXTRW5ITVJ?
MOLT-13	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLkTWM2OD1zMUOuOFQhdk1?	M1;OZnNCVkeHUh?=
NCI-H2170	NUDxU41uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;ETWM2OD1zMUSuOVEhdk1?	NHHBT29USU6JRWK=
HTC-C3	NVH5Um9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfnTHVKSzVyPUGxOk45PSCwTR?=	MmHJV2FPT0WU
LU-99A	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\wemlEPTB;MUG3MlIyKG6P	MnLwV2FPT0WU
HCC2998	NIrMUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPETWM2OD1zMUeuPVIhdk1?	MmT4V2FPT0WU
NB13	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDSTWM2OD1zMUeuPVkhdk1?	NH7k[3JUSU6JRWK=
GT3TKB	MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH65O2NKSzVyPUGxPE4xQCCwTR?=	M1:4VXNCVkeHUh?=
BT-549	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17kXWlEPTB;MUG4Mlk2KG6P	NHvHcWNUSU6JRWK=
NCI-H747	NEHyPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4e4d2lEPTB;MUG5MlM1KG6P	Mn\KV2FPT0WU
EW-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYn0U2pJUUN3ME2xNlAvOiCwTR?=	NFnrdZNUSU6JRWK=
LB831-BLC	NHLoUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnGZoFiUUN3ME2xNlAvPjNibl2=	Mli3V2FPT0WU
NMC-G1	NGnpco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjpTWM2OD1zMkGuNVEhdk1?	MYXTRW5ITVJ?
COLO-679	M1XDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHoTWFKSzVyPUGyNk4yPSCwTR?=	MlOyV2FPT0WU
HL-60	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3Me5VKSzVyPUGyN{4yKG6P	MmPJV2FPT0WU
MKN7	NUn6WFQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfhTWM2OD1zMkOuPFMhdk1?	MljkV2FPT0WU
RERF-LC-MS	M1q4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHr6b5hKSzVyPUGyOE4{OSCwTR?=	M{XwVHNCVkeHUh?=
DMS-114	NGrTU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3UWJlmUUN3ME2xNlUvODlibl2=	NVfvOHlOW0GQR1XS
HuP-T4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3O1UmlEPTB;MUK2Mlk4KG6P	MnjQV2FPT0WU
HCC2157	NEnsZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrGclJKSzVyPUGyO{42KG6P	NX3EfpNGW0GQR1XS
SKG-IIIa	NFO5RldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInSfWlKSzVyPUGyPE45KG6P	Mkf1V2FPT0WU
HCT-116	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\ke5FvUUN3ME2xN\|AvPjRibl2=	M2DTZXNCVkeHUh?=
BB30-HNC	NIjqcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLzTWM2OD1zM{CuO\|ghdk1?	MVPTRW5ITVJ?
KYSE-270	M4LyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTF\|MD64PEBvVQ>?	M{TrcHNCVkeHUh?=
MFM-223	NY\yTmVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLkTWM2OD1zM{GuOVEhdk1?	MUXTRW5ITVJ?
NH-12	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3e0[WlEPTB;MUOyMlk6KG6P	MlnLV2FPT0WU
U-118-MG	M3\IbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHVR2c4UUN3ME2xN\|MvPjJibl2=	M3XrR3NCVkeHUh?=
ESS-1	M1jieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfBT25KSzVyPUGzOU4yQCCwTR?=	NYHQeY9YW0GQR1XS
D-247MG	M1q3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jIXWlEPTB;MUO1MlIyKG6P	NFzDT\|hUSU6JRWK=
IGROV-1	NVjncFBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPITWM2OD1zM{WuO\|Yhdk1?	NGnzZYRUSU6JRWK=
C-33-A	NIDuSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfnTWM2OD1zM{WuPVchdk1?	MVfTRW5ITVJ?
NCI-H1693	NGf1UY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfVPFRpUUN3ME2xN\|YvOTJibl2=	MYnTRW5ITVJ?
MLMA	Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTF\|Nj61PEBvVQ>?	NVOzPWQ3W0GQR1XS
SK-N-AS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\xNoVKSzVyPUGzO{4yPyCwTR?=	MX3TRW5ITVJ?
NCI-H1755	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\UTGlEPTB;MUO4Mlg2KG6P	M3XLcXNCVkeHUh?=
CHP-134	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfjW4ZKSzVyPUGzPU42PSCwTR?=	NELEPHVUSU6JRWK=
LS-513	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHTOplKSzVyPUG0NE46OSCyTR?=	NYTvbGl3W0GQR1XS
TE-12	NWLvR5o5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTF2MD65N{BvVQ>?	MYjTRW5ITVJ?
KNS-42	NVzNbGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmm0TWM2OD1zNESuN{BvVQ>?	NWrtVFRSW0GQR1XS
SJRH30	NWjXNZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fMRWlEPTB;MUS0MlQ1KG6P	MUjTRW5ITVJ?
NCI-H1092	M373[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HQOmlEPTB;MUS0MlUzKG6P	MWDTRW5ITVJ?
H-EMC-SS	MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;mTWM2OD1zNE[uPFEhdk1?	NFXLdIJUSU6JRWK=
SK-MEL-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\PTWM2OD1zNEeuOVUhdk1?	NWTPfVlyW0GQR1XS
SK-N-FI	MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj3W2dKSzVyPUG0O{42QSCwTR?=	M1TLb3NCVkeHUh?=
NCI-H2126	MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfIPWM1UUN3ME2xOFgvOTVibl2=	NFLPcFZUSU6JRWK=
NCI-H1299	MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1:4WWlEPTB;MUWwMlIzKG6P	Mn3tV2FPT0WU
CFPAC-1	NEHldpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTF3MD62OkBvVQ>?	M{n5UHNCVkeHUh?=
NCI-H661	M1S5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIX4Z5FKSzVyPUG1NU4zPiCwTR?=	NF75N2xUSU6JRWK=
KYSE-70	M{PJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\r[ZVZUUN3ME2xOVEvPzlibl2=	MmLWV2FPT0WU
SW900	M{HGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTDTWM2OD1zNUSuOlUhdk1?	MX;TRW5ITVJ?
Ca-Ski	M3HhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TGU2lEPTB;MUW2MlM6KG6P	MX7TRW5ITVJ?
HPAF-II	M1TJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnQTWM2OD1zNU[uOFchdk1?	M3XXUHNCVkeHUh?=
LB2518-MEL	MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvaWpBKSzVyPUG1O{4yKG6P	NYnSWYJqW0GQR1XS
LC-2-ad	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvZfHN7UUN3ME2xOVgvPjJibl2=	MYHTRW5ITVJ?
HCC1806	M2rCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF4Nz64PEBvVQ>?	NVzsRVk2W0GQR1XS
UACC-62	M3\2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPTRmZ7UUN3ME2xOlgvODlibl2=	M1XjNXNCVkeHUh?=
KM-H2	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLwTWM2OD1zN{CuOVghdk1?	MkPNV2FPT0WU
NCI-H2347	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPZTWM2OD1zN{KuO\|Ihdk1?	M3rzUnNCVkeHUh?=
SCC-15	M4\BZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV2zSphyUUN3ME2xO\|MvPjZibl2=	MljjV2FPT0WU
BB49-HNC	MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjxXlJDUUN3ME2xO\|MvQDFibl2=	MkfwV2FPT0WU
GMS-10	M2THbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIftTXFKSzVyPUG3N{46PCCwTR?=	NWWwOG9IW0GQR1XS
NCI-H2052	NETQTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TO[GlEPTB;MUe0Mlkhdk1?	MlrXV2FPT0WU
SW626	NETweFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTF5Nj6wOkBvVQ>?	NIjnXVFUSU6JRWK=
MDA-MB-415	MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfWXGZSUUN3ME2xO\|YvPjFibl2=	NYDvV2wyW0GQR1XS
Saos-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLlTWM2OD1zN{muN\|Uhdk1?	NECxN2lUSU6JRWK=
DK-MG	Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorQTWM2OD1zOECuN{BvVQ>?	MkS3V2FPT0WU
SNU-C2B	NV;5VpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPjZVdwUUN3ME2xPFAvPzNibl2=	MUHTRW5ITVJ?
A427	M33jbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPBTWM2OD1zOEKuOVchdk1?	MlXXV2FPT0WU
KP-N-YS	NH;VV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPrTWM2OD1zOEWgcm0>	NFjZRVVUSU6JRWK=
J82	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\pPWlEPTB;MUi1MlE5KG6P	MVXTRW5ITVJ?
LS-411N	NVHnZ2JwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Pu[2lEPTB;MUi3MlI5KG6P	MoDhV2FPT0WU
HCC1937	NX;BSYt5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTF6Nz60PUBvVQ>?	MYrTRW5ITVJ?
OE33	NXm4cYRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DZNWlEPTB;MUi4Mlk4KG6P	MoPLV2FPT0WU
NB7	NXzpe2tqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\hdWlEPTB;MUi5Mlg6KG6P	NE[2fnRUSU6JRWK=
SW684	M3HUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7aTWM2OD1zOU[uNVMhdk1?	NITCVW1USU6JRWK=
HT-144	NWnDdGRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTF7Nj6xOUBvVQ>?	MU\TRW5ITVJ?
SK-MEL-30	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTF7Nj6yJI5O	M4Ljb3NCVkeHUh?=
DBTRG-05MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrKXXl1UUN3ME2xPVgvPDdibl2=	NYHZUJZGW0GQR1XS
NCI-H1395	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTF7OD64OUBvVQ>?	NYrwSVJKW0GQR1XS
NCI-H2122	NVPLUFI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJyMD61PUBvVQ>?	M2jFe3NCVkeHUh?=
no-10	MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfEUYNiUUN3ME2yNFEvODRibl2=	MmLOV2FPT0WU
SW48	M1SzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHnb5RKSzVyPUKwNU4{OSCwTR?=	NVXaXGlxW0GQR1XS
NCI-H1650	M1rMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUn2cml{UUN3ME2yNFQvODFibl2=	NEjHZm9USU6JRWK=
MZ1-PC	M2noTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HFW2lEPTB;MkC1MlU5KG6P	NWnCXGE1W0GQR1XS
U-266	NU\ZNJhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH23VJpKSzVyPUKwOU44QSCwTR?=	NYfhUI5pW0GQR1XS
CAS-1	NIi2PGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIToeYxKSzVyPUKwO{41PCCwTR?=	NVflfJhxW0GQR1XS
AU565	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7LTWM2OD1{MUKuPFIhdk1?	MWTTRW5ITVJ?
UACC-257	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLWcWZKSzVyPUKxN{46QSCwTR?=	NUHuVphsW0GQR1XS
CAL-27	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJzNz6wOUBvVQ>?	MW\TRW5ITVJ?
NCI-H23	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MluyTWM2OD1{MUmuN\|Mhdk1?	MYTTRW5ITVJ?
TE-6	NUDaPFczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3P1TGlEPTB;MkG5MlY5KG6P	MnvxV2FPT0WU
TGBC24TKB	M1u4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rzNWlEPTB;MkKyMlE4KG6P	NXOwTpl7W0GQR1XS
TE-1	MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzjTWM2OD1{MkKuPFghdk1?	M37BbXNCVkeHUh?=
RCC10RGB	M4fKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmK4TWM2OD1{MkSuNVkhdk1?	MWjTRW5ITVJ?
NCI-H596	NIPacpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PkSWlEPTB;MkK4MlIzKG6P	NGnlcZZUSU6JRWK=
SW954	NEX5flVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfocXdmUUN3ME2yN\|MvQDNibl2=	NVrVbYl6W0GQR1XS
NCI-H2087	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfJTWM2OD1{M{SuOVEhdk1?	M2DJV3NCVkeHUh?=
SK-PN-DW	MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnZTWM2OD1{M{WuNVkhdk1?	M1;FdnNCVkeHUh?=
KM12	MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUGwTXZtUUN3ME2yN\|UvPyCwTR?=	NHLFepZUSU6JRWK=
BT-474	M{i4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PBXmlEPTB;MkO1Mlc{KG6P	NV74XlBLW0GQR1XS
IST-MES1	M2r4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nYWmlEPTB;MkO2MlU4KG6P	M3u3[3NCVkeHUh?=
HT-1197	Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWSzWXdlUUN3ME2yN\|gvODlibl2=	NV[0UGhTW0GQR1XS
CAL-54	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHhTWM2OD1{M{iuOFkhdk1?	NGLYWGpUSU6JRWK=
NB10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnZWoxRUUN3ME2yOFAvODZibl2=	MkDFV2FPT0WU
PANC-10-05	NX7EVYszT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPzbo1KSzVyPUK0OU42PiCwTR?=	Mnj3V2FPT0WU
NCI-H522	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTJ2OD6zNUBvVQ>?	NVHhNW9lW0GQR1XS
A388	NHzPPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfnWIFtUUN3ME2yOFkvQDJibl2=	NVr2R4ROW0GQR1XS
GOTO	MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHtTWM2OD1{NUCuNlkhdk1?	M2f6[3NCVkeHUh?=
KLE	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXv2fo9{UUN3ME2yOVEvQDdibl2=	MmfPV2FPT0WU
KYSE-520	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvQTWM2OD1{NUKuPFYhdk1?	MYnTRW5ITVJ?
HCE-4	M3S5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTJ4Mj61JI5O	MnjTV2FPT0WU
KURAMOCHI	NIKxWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[zcmlEPTB;Mk[1Mlkhdk1?	M1TqXHNCVkeHUh?=
HCC38	NFfjTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLUbJlKSzVyPUK2Ok41QCCwTR?=	MnvDV2FPT0WU
FADU	NFvRe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LMXGlEPTB;Mk[2MlY{KG6P	MXfTRW5ITVJ?
CW-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLZPINVUUN3ME2yOlkvQTZibl2=	MojVV2FPT0WU
L-428	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPwfFF[UUN3ME2yO\|UvOTVibl2=	MlzBV2FPT0WU
HCC1569	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vxZ2lEPTB;Mke1Mlg1KG6P	MX3TRW5ITVJ?
NCI-H810	MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTJ5OD6zNUBvVQ>?	MnLuV2FPT0WU
LB771-HNC	NW\1UpVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LITmlEPTB;Mki1Mlg1KG6P	M{L1SXNCVkeHUh?=
LCLC-103H	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3aW3RnUUN3ME2yPFUvQTlibl2=	NHz0OFZUSU6JRWK=
EFO-21	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnU[INIUUN3ME2yPFcvPjhibl2=	MV\TRW5ITVJ?
CAL-72	M2[4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1P2[WlEPTB;MkmzMlE6KG6P	NITSdJdUSU6JRWK=
SCC-9	M3[2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1voUWlEPTB;MkmzMlIzKG6P	MoTtV2FPT0WU
COLO-829	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGO3bXVKSzVyPUK5Ok42KG6P	NGDLWpNUSU6JRWK=
U-87-MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTNyMD63N{BvVQ>?	NYPlfok6W0GQR1XS
MZ7-mel	M1XHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TzbmlEPTB;M{KzMlc3KG6P	MkLiV2FPT0WU
NCI-H1770	MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XyOWlEPTB;M{K2Mlc1KG6P	NHm2Z4lUSU6JRWK=
ChaGo-K-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PiPWlEPTB;M{K4MlEhdk1?	M2C3eXNCVkeHUh?=
SiHa	M2PNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPXRYV4UUN3ME2zNlkvOjRibl2=	NXHnVnp2W0GQR1XS
NCI-SNU-5	NVfqV2UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLOfoduUUN3ME2zN\|YvPzdibl2=	MnjIV2FPT0WU
DJM-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HLN2lEPTB;M{SwMlM{KG6P	Mn\ZV2FPT0WU
OE19	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTN2MD61N{BvVQ>?	NWnsPYd7W0GQR1XS
NCI-H1651	MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7TTWM2OD1\|NESuNVghdk1?	NGDwUGpUSU6JRWK=
COLO-792	NUPFT2FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n2NWlEPTB;M{W0MlQzKG6P	NULIW4N1W0GQR1XS
ACHN	NIrRUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTN3Nj63NUBvVQ>?	NES2VGlUSU6JRWK=
TH-3	M3S2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTN5OT65OUBvVQ>?	M3TKRXNCVkeHUh?=
HT-1376	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoiwTWM2OD1\|OESuPFghdk1?	M2rLfHNCVkeHUh?=
RH-18	NWTzPI9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXRb3BKSzVyPUO5OE44PCCwTR?=	MWjTRW5ITVJ?
NB6	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LtWWlEPTB;M{m2MlY3KG6P	MX7TRW5ITVJ?
COLO-320-HSR	NHHmPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{H4RmlEPTB;NECzMlM4KG6P	NFfXbXZUSU6JRWK=
UACC-893	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\ITWM2OD12ME[uOFchdk1?	MU\TRW5ITVJ?
DSH1	NFTxTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTRyNj65NUBvVQ>?	Moi3V2FPT0WU
TE-10	M4fsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2na[mlEPTB;NEC3MlAyKG6P	NYWzdGlsW0GQR1XS
HCC70	NUHrcoJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTRyOT6yNUBvVQ>?	MWXTRW5ITVJ?
TGBC11TKB	M3\5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LCOWlEPTB;NEGwMlM{KG6P	NUjIVHU1W0GQR1XS
NCI-H727	NGTHb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELWbZdKSzVyPUSxNk4yOSCwTR?=	NUjw[lFOW0GQR1XS
ALL-PO	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrYd\|FKSzVyPUSxOU43QSCwTR?=	Mk\aV2FPT0WU
ABC-1	MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr0cJZKSzVyPUSyNE41PSCwTR?=	Mn22V2FPT0WU
NCI-H69	NH\kV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvZN4RpUUN3ME20NlYvPzZibl2=	MoXGV2FPT0WU
GP5d	MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jibWlEPTB;NEO0MlQyKG6P	NEX0PG9USU6JRWK=
UMC-11	NXTpUnNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTR3OD6zOkBvVQ>?	MV7TRW5ITVJ?
RMG-I	M4\2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlOwTWM2OD12NkeuOVYhdk1?	NYrvV4prW0GQR1XS
YAPC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHQSotKSzVyPUS5NE43KG6P	NFnPfFJUSU6JRWK=
LS-1034	M1zQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTDfXRpUUN3ME20PVEvODZibl2=	NIXLZnlUSU6JRWK=
RCM-1	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLj[oVKSzVyPUS5Ok43QCCwTR?=	NGHJfnBUSU6JRWK=
HCC1954	MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEi1ZlBKSzVyPUWxNk42KG6P	NFHtPVhUSU6JRWK=
SK-MEL-24	NV\QZ4tHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHnfI0{UUN3ME21NVYvPTFibl2=	NWP6OnJFW0GQR1XS
NB12	NGrINWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[1bmlEPTB;NUK4MlQzKG6P	MkizV2FPT0WU
SW756	NF\pd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknVTWM2OD13NUSuPVYhdk1?	M13lZnNCVkeHUh?=
HCC1187	M1Hycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;YZm9KSzVyPUW3OU45OyCwTR?=	MVHTRW5ITVJ?
NCI-H2342	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3PXpRKSzVyPUW5NE4{QSCwTR?=	MUnTRW5ITVJ?
NCI-H2291	NHf1XmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2Hjd2lEPTB;NUm4MlMyKG6P	NHnYUnpUSU6JRWK=
OVCAR-3	NGjG[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nBVWlEPTB;NUm4Mlk3KG6P	NUPMU5dmW0GQR1XS
MHH-NB-11	NV;oT5BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIK2PXdKSzVyPU[yPU4xOSCwTR?=	NYPFepFlW0GQR1XS
SAS	M4[4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml2yTWM2OD14NUKuOlchdk1?	M{W3SXNCVkeHUh?=
COLO-824	M{GwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TxUmlEPTB;Nki5MlM4KG6P	NHLYclFUSU6JRWK=
HCC1395	NVPGcm96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPLTWM2OD14OUiuOUBvVQ>?	M2LMTnNCVkeHUh?=
COLO-668	M3zhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4ewOGlEPTB;N{C2MlEhdk1?	NVLXbY1NW0GQR1XS
NCI-H226	Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3ZTWM2OD15MEeuPEBvVQ>?	MlXEV2FPT0WU
NB17	MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDXTWM2OD15MkGuO\|Uhdk1?	NWfRTXZlW0GQR1XS
SW1463	NF3OfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFv4UJRKSzVyPUezPU4yQSCwTR?=	Ml;PV2FPT0WU
TGW	M1r6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\WbmlEPTB;N{[wMlE2KG6P	NYXlOpRtW0GQR1XS
NCI-H526	NFnrZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rJSGlEPTB;OEKzMlU{KG6P	MYPTRW5ITVJ?
COR-L88	MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXv6fo5CUUN3ME24OFgvOTJibl2=	NG[xUlFUSU6JRWK=
NCI-H441	NWfYc5Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTh7NT6yNkBvVQ>?	MVPTRW5ITVJ?
NCI-H630	Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4K3cWlEPTB;OUGyMlk3KG6P	M{PXXXNCVkeHUh?=
Mo-T	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4q1VWlEPTB;OUS3Mlg5KG6P	NWThU5kyW0GQR1XS
JAR	M4\yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jDXGlEPTB;OUW2MlI1KG6P	NYj2flJKW0GQR1XS
NCI-H1838	MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\iTWM2OD1zLkCyN\|g5KM7:TR?=	NEfSOYRUSU6JRWK=
DoTc2-4510	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTFwMEezO\|Yh\|ryP	M33mc3NCVkeHUh?=
MKN28	NGLqPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTFwMEmwNlQh\|ryP	MXjTRW5ITVJ?
HuP-T3	NE\SZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rPTGlEPTB;MT6xNVkxPSEQvF2=	NUPOcnlvW0GQR1XS
TE-9	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETV[WJKSzVyPUGuNVI6PzNizszN	NHzNVGtUSU6JRWK=
NY	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTFwMU[3PVIh\|ryP	NWTtS2R4W0GQR1XS
HT55	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjBWlhKSzVyPUGuN\|E{PDRizszN	NEXCeVVUSU6JRWK=
SW837	NUL1fHJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPmTWM2OD1zLkOyPVc5KM7:TR?=	MX3TRW5ITVJ?
NCI-H2029	M4q0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3ywNWlEPTB;MT60NVc6OSEQvF2=	NFfPVphUSU6JRWK=
IST-SL1	NULjVoE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXWTWM2OD1zLkS0NlQh\|ryP	NVTseVhkW0GQR1XS
COLO-741	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFH4[opKSzVyPUGuOFk4PzFizszN	NUHrUm93W0GQR1XS
LU-65	NW\kb3F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFwNkKyOFkh\|ryP	MWLTRW5ITVJ?
NCI-H1304	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTFwNkW0PVgh\|ryP	NXficYtjW0GQR1XS
KARPAS-299	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\JV2lEPTB;MT63PVQ4QSEQvF2=	NWTMS\|ZTW0GQR1XS
NCI-H358	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;xVYlKSzVyPUGuPVU2ODNizszN	MYDTRW5ITVJ?
OAW-28	NFvwdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HtdWlEPTB;Mj6wOlkyQSEQvF2=	NGG4PWdUSU6JRWK=
C8166	NYHPNmg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fXcWlEPTB;Mj62N\|M6OiEQvF2=	NIe5elZUSU6JRWK=
COLO-678	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7zTWM2OD1{LkizO\|Y5KM7:TR?=	NGLrVFlUSU6JRWK=
SK-N-DZ	MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnn2TWM2OD1{Lki2N\|gyKM7:TR?=	M1zyTnNCVkeHUh?=
NCI-H82	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTJwOUCzOlkh\|ryP	M2jYdXNCVkeHUh?=
JVM-2	M2HaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTNwMEOxPFgh\|ryP	M2TGOXNCVkeHUh?=
SW1116	MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnqTWM2OD1\|LkC1OFEyKM7:TR?=	Mn25V2FPT0WU
MDA-MB-453	NXK1[\|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTNwMUC0N\|kh\|ryP	M{\i[3NCVkeHUh?=
Calu-6	M4\yN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrDV3REUUN3ME2zMlE6QTdizszN	NUXLWo9zW0GQR1XS
SHP-77	NF:4ZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXPTWM2OD1\|LkWyPEDPxE1?	MXTTRW5ITVJ?
Capan-2	NFPXUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTSfFBKSzVyPUSuN\|I2QDFizszN	M3PvSXNCVkeHUh?=
SW948	NH7vTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7WNlVlUUN3ME20Mlc1Pzd7IN88US=>	NWSyfnBPW0GQR1XS
HDLM-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTVwMEe3NlUh\|ryP	M13rR3NCVkeHUh?=
LAN-6	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzuZoU4UUN3ME22MlIyPDl3IN88US=>	M2C2ZXNCVkeHUh?=
LU-135	MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moi5TWM2OD14LkSzNFc4KM7:TR?=	NXz6eW0{W0GQR1XS
T84	NFm2U5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfXe5d[UUN3ME22Mlk5PjRizszN	MmXqV2FPT0WU
CAPAN-1	Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jSbWlEPTB;Nz62NlI{OyEQvF2=	NVvxRWhWW0GQR1XS
SW1417	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTdwOUG3N\|Eh\|ryP	MlzYV2FPT0WU
BALL-1	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmr5TWM2OD16LkWwOFA6KM7:TR?=	NHnTO2tUSU6JRWK=
HT-29	NVXrXGZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;QRZJKSzVyPUmuNFc2QTlizszN	NGHYSIZUSU6JRWK=
C3A	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nv[2lEPTB;OT64PFM6PCEQvF2=	MVPTRW5ITVJ?
NCI-H1993	NUnCVIdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTMd4tKSzVyPUGwMlUxQDFizszN	M3j5dnNCVkeHUh?=
SK-MEL-1	NW\pcFZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPKNIJEUUN3ME2xNU43Ojh7IN88US=>	NHnGWHpUSU6JRWK=
DU-145	M{XrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rLcWlEPTB;MUSuOVA2OiEQvF2=	NHyyUGFUSU6JRWK=
KP-N-YN	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3FTWM2OD1zND61NVA{KM7:TR?=	NH7LdYRUSU6JRWK=
CCRF-CEM	M4GwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrQR4dKSzVyPUG0Mlc5ODlizszN	MX7TRW5ITVJ?
ZR-75-30	NXLwT2FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3P4U2lEPTB;MU[uN\|MxOyEQvF2=	MWrTRW5ITVJ?
A673	NIrlUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTJyLkW1NFch\|ryP	NV\QTHJ1W0GQR1XS
K-562	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHn6doRKSzVyPUK4MlQyQDNizszN	MWHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	+ Expand Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Female Harlan athymic nude mice Formulation: NMP/polyethylene glycol 300 (10/90, v/v) Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+polyethylene glycol 300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03373903	Active not recruiting	Respiratory Tract Infections	Restorbio Inc.	November 15 2017	Phase 2
NCT03373903	Active not recruiting	Respiratory Tract Infections	Restorbio Inc.	November 15 2017	Phase 2
NCT01856101	Terminated	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01856101	Terminated	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01717898	Terminated	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products5

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 88 Publications

11 Customer Reviews

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 88 Publications

11 Customer Reviews

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)